NCT03686787

Oral Tranexamic Acid and Laser for Treatment of Melasma

The Efficacy of Oral Tranexamic Acid and a 1927 nm Diode Laser in Patients With Melasma. A Prospective Randomized Split Face Study

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 32 (estimated)
• Sponsor: Laser and Skin Surgery Center of New York · Academic / Other
• Sex: All
• Age: 18 Years – 50 Years
• Healthy volunteers: Accepted

Summary

Tranexamic acid and 1927 diode laser non-ablative fractionated laser for the treatment of Melasma.

Detailed description

Seeking healthy non-smoking male and female volunteers of all skin types of age 18 to 50 with moderate melasma or severe melasma. Participants will receive up to 5 monthly laser treatments to half the face and need to take a pill twice a day for 4 months. Follow up visits are required 1 month, 3 months and 6 months after the final treatment. Compensation of up to $150 will be provided based on completed visits.

Conditions

• Melasma

Interventions

Type	Name	Description
DRUG	Tranexamic Acid	A split face study of oral tranexamic acid in combination with laser treatment

Timeline

• Start date: 2018-10-01
• Primary completion: 2019-07-31
• Completion: 2019-10-01
• First posted: 2018-09-27
• Last updated: 2018-09-27

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study